Thomas James Lynch MD

Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology); Director, Yale Cancer Center; Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven

Departments & Organizations

Cancer Center, Yale: Thoracic Oncology Program | Developmental Therapeutics

Internal Medicine: Medical Oncology


Dr. Lynch is Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven. The Richard Sackler and Jonathan Sackler Professor of Medical Oncology, Dr. Lynch is an expert in the treatment of lung cancer with a special interest in personalized medicine. Dr. Lynch received his undergraduate degree from Yale College in 1982 and his MD degree from Yale School of Medicine in 1986. He completed his internship and residency at MGH, and after serving a fellowship in medical oncology at the Dana-Farber Cancer Institute, he joined the medical staff at the Massachusetts General Hospital in 1993. In 1996, he helped found the Boston-based Kenneth B. Schwartz Center for the Promotion of Caregiver/Patient Relations and became vice chair of its board of directors in 2006. He began his tenure as Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven on April 1, 2009.

Dr. Lynch has made important contributions in developmental therapeutics and in defining the optimal treatment for patients with lung cancer. He has pioneered the use of molecular testing for mutations in the epidermal growth factor receptor gene to select patients who can benefit from targeted lung cancer therapies. He is the author of numerous publications and maintains a vigorous clinical practice.

Dr. Lynch also oversees a new institute for cancer biology at Yale’s 136-acre West Campus, for which he will be recruiting a director and senior and junior scientists in the fields of cell signaling, cancer immunology and drug development and target acquisition.


  • B.S., Yale University , 1982
  • M.D., Yale University School of Medicine , 1986

Selected Publication

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ann Oncol. 2013 Jan;24(1):75-83.
Download on the Apple App Store